Open an account

Turn Therapeutics

TTRX · NASDAQ

$10.47−$0.27 (−2.51%)TodayMarket closed ·
Prev close $10.74

About TTRX

Turn Therapeutics, Inc. is a pharmaceutical and medical device development company. The company is headquartered in Westlake Village, California. The company went IPO on 2025-10-08. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.

Employees
0
Headquarters
Westlake Village, California
Listed
Oct 8, 2025
Sector
Health Care
Industry
Pharmaceuticals
Website
turntherapeutics.com

TTRX key statistics

Market cap
319.92M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
108.69K
Volume
76.91K
Open price
$10.54
High today
$10.74
Low today
$10.28
52 Week high
$16.45
52 Week low
$2.57

Turn Therapeutics (TTRX) at a glance

As of Oct 20, 2026, Turn Therapeutics (TTRX) shares are priced at $10.47, giving the company a market cap of 319.92M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $10.28 and $10.74. The current price is 1.8% above the day's low and 2.5% below its high.

Volume so far is 76.91K shares, below the average of 108.69K shares a day.

Over the past year Turn Therapeutics has ranged from $2.57 to $16.45, and now sits 57% of the way up that range.

Turn Therapeutics met or beat analyst EPS estimates in 1 of the last 3 quarters. In Q2 FY26 it reported -$0.06 per share against an estimate of -$0.0255.

The average analyst price target is $20.40, 94.8% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold0.0%
  • Sell33.3%
Price target · 5 analystsAvg $20.40
Low
$10.10
Now
$10.47
High
$27.30

TTRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 3 quarters, by 124.5% on average.

  1. Q4 FY25: reported $0.01 per share against an estimate of -$0.0408
  2. Q1 FY26: reported -$0.026 per share against an estimate of -$0.0255
  3. Q2 FY26: reported -$0.06 per share against an estimate of -$0.0255

TTRX news

  • Press releaseBusiness Wire

    Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

  • Press releaseBusiness Wire

    Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer

  • Press releaseBusiness Wire

    Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

  • Press releaseBusiness Wire

    Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

  • Vandana Singh

    Why Is Turn Therapeutics Stock Trading Higher Today?

  • Press releaseBusiness Wire

    Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

  • Press releaseBusiness Wire

    Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

Similar companies

Companies in the same industry as Turn Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.